Ascelia Pharma AB (publ) (STO:ACE)

Sweden flag Sweden · Delayed Price · Currency is SEK
3.855
+0.060 (1.58%)
May 9, 2025, 5:29 PM CET
-63.49%
Market Cap 370.49M
Revenue (ttm) n/a
Net Income (ttm) -80.03M
Shares Out 96.11M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE 25.14
Dividend n/a
Ex-Dividend Date n/a
Volume 725,869
Average Volume 849,689
Open 3.850
Previous Close 3.795
Day's Range 3.795 - 3.955
52-Week Range 1.889 - 11.680
Beta 0.99
RSI 71.14
Earnings Date May 16, 2025

About Ascelia Pharma AB

Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology. Ascelia Ph... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 11
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACE
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.